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Abstract
Combinatorial approaches that integrate conventional pathology with genomic profiling and
functional genomics have begun to enhance our understanding of the genetic basis of breast
cancer. These methods have identified key genotypic-phenotypic correlations in different breast
cancer subtypes that have led to the discovery of genetic dependencies that drive their behavior.
Moreover, this knowledge has been applied to define novel tailored therapies for these groups of
cancer patients. With the current emphasis on characterizing the mutational repertoire of breast
cancers by next generation sequencing, the question remains as to what constitutes a driver event.
By focusing efforts on homogenous subgroups of breast cancer and integrating orthogonal data-
types combined with functional approaches, we can begin to unravel the heterogeneity and
identify aberrations that can be therapeutically targeted.
Introduction
Traditionally, breast cancers have been characterized into biologically and clinically
meaningful subgroups according to histological grade and type (i.e. growth pattern)(1), with
the majority of breast cancers being classified by histological exclusion i.e. invasive
carcinomas of no special type (IC-NST). On the other hand the remaining tumors can be
histologically classified according to their distinctive growth patterns and are termed
‘special’ histological types. Over the last decade seminal class discovery expression
profiling studies have identified a number of molecular subtypes of breast cancer defined at
the transcriptomic level that are characterized by distinct histological features, clinical
behaviors and responses to therapy(2). Indeed, different breast cancer subtypes (both
histological and molecular) harbor distinct patterns of genetic aberrations and are driven by
alterations in distinct molecular pathways and networks(3, 4). It is now widely accepted that
breast cancer heterogeneity may be underpinned by myriad mechanisms of genetic
aberration (e.g. gene amplifications, in-frame fusion genes or mutations and homozygous
deletions, disrupting fusions or deleterious mutations causing gene activation or inactivation
respectively), and that phenotypic subgroups harbor distinct patterns of genomic
aberrations(3, 5). Moreover, targeting these genomic alterations has proven an effective way
of developing tailored therapies for subgroups of breast cancers(5-9).
The use of high-throughput technologies has enabled the investigation of biological
phenomena and allowed its correlation to specific disease behavior. Research has focused on
integrative approaches combining high-throughput genomic data through the use of
microarray-based comparative genomic hybridization (aCGH), gene expression profiling
and more recently the use of next generation sequencing, to define the genetic underpinning
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of different subtypes of cancer with the ultimate goal of identifying novel therapeutic
targets. However the main challenges for the translation of the genetic alterations identified
by massively parallel sequencing into benefit for cancer patients lie in the identification of
biologically relevant aberrations among the deluge of sequencing data being produced,
which can be used as therapeutic targets or predictive biomarkers.
Exploring genotypic-phenotypic correlations
There is evidence to suggest that at least some subtypes of breast cancer are underpinned by
distinct arrays of genomic alterations. In fact some special histological types of breast cancer
harbor specific pathognomonic alterations such as the ETV6–NTRK3 oncogenic fusion gene
in secretory carcinomas, the MYB-NFIB fusion gene in adenoid cystic carcinomas, and
inactivation of E-cadherin through mutation and gene methylation in lobular carcinomas of
the breast (for a review on special histological types of breast cancer see(10)). Perhaps the
best example in breast cancer is the characterization of ERBB2 (HER2) as the driver of the
17q12 amplification, which has spurred the hunt for additional amplified driver events. We,
and others have explored the genotypic–phenotypic correlations of different molecular
subgroups of breast cancers through the use of high-throughput genomic analyses using
aCGH(3, 5). Through aCGH profiling of a series of 95 high-grade breast cancers, we have
shown that distinct patterns of copy number alterations are found in different molecular
subtypes(5). These analyses highlighted the genotypic-phenotypic association between
specific amplifications and subtypes of breast cancer(3, 4).
Integrating data-types to identify therapeutic targets
By using a combination of aCGH and gene expression profiling, we have shown that
canonical pathways involved in estrogen receptor (ER) signaling, proliferation and DNA
repair are enriched for genes whose expression is driven by copy number in basal-like,
HER2 and luminal tumors(3), suggesting that the diversity of breast cancer and the
molecular subtypes may stem, to some degree, from the different patterns of genetic
aberrations found in these cancers. Moreover, biological phenomena characteristic of each
subtype (e.g. proliferation, HER2 and ER signaling) may be driven by specific patterns of
copy number aberrations. This approach has also led to the identification of genes that are
consistently overexpressed when amplified, which are considered potential ‘amplicon
drivers’. However not all genes within an amplicon are overexpressed, and an amplicon may
harbor more than one driver(6). The expression of some driver genes is also more pervasive
i.e. are overexpressed by other mechanisms in addition to amplification. That said, such
approaches have been successful in identifying novel targets for subgroups of breast cancer,
by exploiting the concepts of oncogene addiction. For instance, FGFR1, one of the genes
mapping to the 8p11-p12 amplicon, is amplified in 10-15% of breast cancers and is
associated with ER-positive disease and poor survival(11). FGFR1 is consistently
overexpressed in tumors harboring FGFR1 amplification both of which have been shown to
constitute a mechanism of resistance to endocrine therapy(9). A phase II clinical trial is
currently testing the efficacy of small molecule FGFR inhibitors for these patients. By
performing genome wide correlations between amplifications in different subgroups of
breast cancer, we have identified a number of subgroup specific amplifications. This
approach, coupled with integrating these data with matched gene expression data led to the
identification of PPM1D as a putative amplicon driver(5). RNA interference-induced
silencing and chemical inhibition of PPM1D in a panel of phenotypically matched PPM1D
amplified and non-amplified cells showed that PPM1D expression and phosphatase activity
is selectively required for the survival of cells harboring PPM1D gene amplification(5, 12).
These data suggest that PPM1D may prove a viable therapeutic target for the subset of
HER2-positive breast cancers harboring amplification at 17q23.2. Through a similar
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approach, we identified 38 genes that were significantly overexpressed when amplified in a
series of 56 triple negative breast cancers, including FGFR2 amplifications in approximately
4%. Our work demonstrated that cancer cells harboring FGFR2 amplification are exquisitely
sensitive to inhibition of FGFR2 in vitro and in vivo through the use of RNA interference
and treatment with FGFR small molecule inhibitors [8], suggesting that FGFR inhibitors
may constitute a tailored therapy approach for a subgroup of triple negative tumors. More
recently, we have shown that 5% of ER-negative high-grade breast cancers that harbor
amplification of CCNE1 within the 19q12 amplicon are dependent on CCNE1 and CDK2
kinase activity for their survival. Cancer cells with CCNE1 gene amplification are sensitive
to CDK2 inhibitors, providing a rationale for the testing of these chemical inhibitors in a
subgroup of patients with ER-negative grade III breast cancers in the context of clinical
trials(6).
As well as using genetic and transcriptomic data to identify potential therapeutic targets in a
candidate driven approach, integrating functional profiling data offers an unbiased way of
identifying genetic dependencies. This approach has been used to identify additional
amplicon drivers in HER2 amplified tumors by systematically assessing cell viability in a
panel of HER2 amplified cell lines after silencing of all genes that were significantly
overexpressed when amplified identified in a cohort of primary HER2 amplified breast
cancers. This approach identified the transcription factor TFAP2C as a novel genetic
dependency in 5% of HER2 amplified breast cancer cells(13). Whilst such screening
approaches as these can identify novel amplicon drivers, many of the targets identified (e.g.
transcription factors) are not directly targetable. By exploiting the concept of synthetic
lethality(7), (where loss of either gene is compatible with cell survival, however loss or
inhibition of both genes results in cell death), the alterations in the cells’ physiology that
arise as a consequence of aberrant activation of oncogenes or tumor suppressor gene loss,
rather than oncogene/tumor suppressor proteins themselves, are targeted to achieve tumor
selectivity. This concept has been successfully applied to identify novel therapeutic targets
including PARP inhibitors in BRCA1/2 mutant patients, further corroborated by the
identification of a resistance mechanism to PARP inhibitors(14). High-throughput RNA
interference screening of the kinome (i.e. pharmacologically tractable genes), in a panel of
commonly used breast cancer cell line models, identified a series of novel genetic
dependencies, in basal, luminal and HER2 subgroups(15). This approach also led to the
identification of genetic dependencies of cells with specific mutations, e.g. PTEN-null breast
tumor cells were found to be dependent on signaling through mitotic checkpoint kinases.
Integration of viability data with transcript and protein profiling also identified a correlation
between sensitivity to ADCK2 silencing and high ADCK2 mRNA and protein levels in ER-
positive cells(15). Such unbiased approaches provide a framework upon which additional
dependencies and candidate therapeutic targets may be identified.
The next generation
The advent of next generation sequencing has increased our understanding of the complexity
of cancer genomes tremendously and has identified a number of subtype-specific mutations
associated with different cancer types. Massively parallel sequencing studies in breast
cancer have identified a plethora of novel mutations, including MAP3K1 mutations in ER-
positive cancers(16), and PARK2 mutations in triple negative disease(17). In addition RNA-
sequencing studies have enabled the identification of novel recurrent targetable expressed
fusion genes, involving the MAST kinase and NOTCH gene family members(18). Large-
scale sequencing efforts currently being undertaken with consortia such as The International
Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), are leading to
an unprecedented amount of data. However, the main challenges that lie ahead are for the
translation of the genetic alterations identified by next-generation sequencing into benefit for
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cancer patients. These mainly depend on i) the identification of ‘driver’ mutations and ii) the
targeting of ‘driver’ genetic aberrations. While the identification of ‘driver’ genetic
aberrations so far has been largely based on statistical algorithms(19), the targeting of the
‘driver’ aberrations has proven difficult. However, the majority of the novel mutations
observed in the common types of breast cancer are at relatively low frequency, and the main
challenge lies in the distinction of what constitutes a ‘driver’ mutation event versus a
‘passenger’ event (i.e., has no biological significance on the cell harboring its mutation at a
given point in time)(7).
Traditionally, the identification of driver events stems from the fact that they are recurrent at
a significant frequency above the background mutation rate within the tumor cohort studied.
We can integrate different sorts of genetic alterations to aid the identification of recurrent
activation or tumor suppressive events, such as mutation and homozygous deletions, or
gross DNA rearrangements of a tumor suppressor gene, or amplification and activating
mutations of an oncogene (Fig. 1). We have used this approach to identify novel candidate
cancer genes in BRCA1 mutant tumors, by integrating a list of mutations identified from
whole genome sequencing, with published aCGH data for the presence of homozygous
deletions(20). This can also be taken further to look for functional recurrences in the form of
genetic alterations in members of the same gene family or members of the same signaling
network or pathway. For example mutations in chromatin remodeling genes appear to be a
common alteration in many types of solid tumors(19, 21), and identifying ways of targeting
these tumors with chromatin remodeling defects is a key challenge that needs to be explored
in future studies. There are a number of computational tools that exist to predict the
functional effect of a mutation of interest on a protein and to identify pathways that are
deregulated in cancer and therefore are likely to contain significant driver genes. Algorithms
that identify key transcriptional regulators of oncogenic programs can be used to prioritize
mutations for follow-up studies (for a review of these see(22)). Algorithms that predict the
pathogenicity of somatic mutations based on the selection pressure and type of mutation
have also been developed(19, 23). However, novel predicted ‘drivers’, still need to be
functionally investigated in appropriate model systems before they can be definitively
defined as driver events. The recent functional validation of HER2 mutations in breast
carcinomas without HER2 amplification has highlighted the importance of this step(24).
Through the use of functional genomic screens we can begin to identify driver events in a
high-throughput manner. This can be achieved a number of ways, from cross-species
comparative approaches identifying driver genes as those that are conserved in human and
mouse tumors, high-throughput insertional mutagenesis screens through to whole genome
shRNA screens(22). Perhaps a more intuitive approach, which aids in the identification of
both tumor suppressor genes and oncogenic drivers lies in the generation of cancer genome
focused screens by generation of overexpression libraries of mutant open –reading frames
(ORF’s) and short hairpin RNA’s (shRNA’s) that target the same set of genes identified by
sequencing primary tumor samples. These libraries can then be screened for their ability to
transform pre-malignant cells. In addition, wild-type ORF libraries generated from primary
tumors without prior knowledge of the mutations may also provide an effective approach for
gain of function screens.
As many mutations and fusion genes identified may not be directly targetable, synthetic
lethality approaches constitute an alternative for the identification of novel targets. These
can be achieved through screening of isogenic cell line models with and without the
genomic alteration of interest and/or a panel of heterogeneous cell lines with and without the
alteration, with si/shRNA screens of druggable genes and high-throughput small molecule
drug screens. Through the use of drug screens using small molecule inhibitors that are
already FDA approved, the time needed from target identification to phase II clinical trials is
much shorter. In fact there are a plethora of small molecule inhibitors available that have no
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useful predictive biomarker. Identifying these biomarkers through these integrated
approaches would ultimately lead to patient benefit more quickly. Concerted efforts within
the scientific community are being aimed at addressing these issues, and interrogation of
systematic pharmacogenomic screening data for an aberration of interest is becoming a
reality(25, 26). In parallel, the growing field of metabolomics is yielding interesting
possibilities for classifying tumors based on their metabolic signatures, and in identifying
pathways related to drug resistance or toxicity through metabolomic profiling. Furthermore,
metabolic dependencies resultant from specific genomic alterations, offer novel therapeutic
opportunities. Readers are directed to excellent reviews on the subject(27). In addition, other
factors such as the importance of epigenetic mechanisms (including methylation and
acetylation)(28) and non-coding RNAs upon gene regulation(29), and the role of the tumor
micro-environment need also to be considered(30, 31).
However, not all recurrent mutations and fusion genes are represented by the available
breast cancer cell line models, and pathognomonic events underlying some types of breast
cancer can only be studied in the context of forced expression models, making the use of
synthetic lethal approaches limited. Such models may not recapitulate the network state
space of primary tumors harboring the genetic aberration of interest. These caveats must be
born in mind when interpreting pre-clinical functional validation data. That said, there are a
number of common genetic aberrations which are not directly targetable (e.g. TP53 and
KRAS mutations, and PTEN loss of function), where adequate models are in abundance.
This provides an opportunity to leverage the power of synthetic lethal screens in multiple
isogenic models, thereby providing some control for the context-dependent nature of many
genetic dependencies. Furthermore, by subjecting samples with and without the mutation of
interest to deep sequencing one might identify a pattern of co-mutation (e.g. are there a set
of genes frequently mutated in TP53-mutant triple negative breast cancers but not in TP53
wild type cancers), which could be modeled in vitro through synthetic lethal screens to
interrogate potential cooperative interactions. Systems biology approaches would likely
prove invaluable in these strategies.
Finally, next generation sequencing studies have highlighted the scope(32) and important
role of intra-tumor genetic heterogeneity in cancer evolution and emergence of drug
resistance(33). High depth multi-region sequencing and single cell sequencing can be used
to characterise the repertoire somatic variants or patterns of copy number changes in non-
modal clones within a tumor. Of course, not all these mutations will be biologically relevant.
Integration of these data with pathway analysis tools and on-line resources such as the
Connectivity Map(34) which identifies connections between drugs, disease and genes, aids
prioritization of mutations and subsequent compound library screening, using chemical
libraries of drugs currently in clinical trials. This approach would identify which mutations
confer resistance to which drug; the ideal scenario would then be to analyze pre- and post-
treatment samples from neoadjuvant trials to confirm the role of these non-modal clones in
the evolution of drug resistance. Focused high depth sequencing could be effectively
employed as a screening strategy to exclude patients from treatment with agents they are
likely to develop resistance to, or early relapse after.
Summary
Integration of multiple data-types is becoming increasingly useful for the identification of
therapeutic targets, within different subtypes of breast cancer. With the advent of next
generation sequencing technologies and the vast amounts of data being generated, it is
possible to identify recurrent mutational patterns within breast cancer. However, given the
relatively low frequency of novel mutations and fusion genes in breast cancer and to fully
understand the biology and therapeutic responses of some patients, the clonal genotypes of
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the individual tumors will need to be determined. It is evident that these large-scale
sequencing projects need to be integrated with functional screens to achieve the goal of
developing novel therapeutic strategies. For functional screening to be useful in identifying
key driver events, researchers need to account for the fact that many gene alterations will be
context dependent; either through epistatic interactions, or dependence on a particular
developmental stage of the tumor. It will be necessary to develop more complex models to
assess interactions in a more network-driven approach. The goal of individualized patient
management will be a step closer with the inception of clinical trials designed to perform
genome-wide or targeted sequencing of cancers to identify targetable aberrations and to
determine the mechanisms of resistance to specific therapeutic agents.
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FIGURE 1. Schematic of data integration to identify therapeutic targets
Molecular profiling of a cohort of primary breast cancers allows the identification of
genomic alterations. Integration of this data is useful to identify potential oncogenic and
tumor suppressive events in silico; e.g. genes that are overexpressed when amplified, in-
frame fusion genes where the 3′ partner is overexpressed, mutations that are expressed at
the mRNA level; genes that are under-expressed when deleted or methylated, disrupting
fusions/structural rearrangements or mutations resulting in under-expression respectively.
Additional in silico analyses can be performed to identify potential candidate driver genes
by using prediction algorithms that ascribe biological meaning to genomic data. For example
searching for significantly altered pathways that are more likely to contain driver genes,
prediction of key transcriptional regulators of oncogenic programs and prediction of which
missense mutations are likely to have a biological effect on the protein. Construction of
cancer-focused screens can be a useful tool to investigate which candidate driver genes
confer tumor specific dependencies. Oncogenic drivers and tumor suppressors are
simultaneously assessed by constructing parallel libraries of cDNA ORF’s and shRNA’s,
which are expressed in pre-malignant cells, and subsequently assayed for tumorigenicity
either in vitro through the use of 3D models or in vivo. In addition, other measures of
phenotypic alterations can also be assayed in tandem e.g. invasion, migration and resistance
to anoikis. Both pooled screening using next generation sequencing for deconvolution and
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identification of biologically active ORF’s and shRNA’s, or single well screening can be
used. To take forward hits from these screens, the use of appropriate cancer cell line models
constitutes a more translationally relevant platform for drug discovery and development.
Either a panel of phenotypically matched breast cancer cell lines (ER, PR, HER2, TP53)
with and without the aberration of interest are used, or an isogenic cell pair to investigate the
selectivity of the genomic alteration of interest. Genes that are directly targetable with
validated inhibitors (e.g. kinases) can then be taken forward for further evaluation in the cell
line panel e.g. for oncogenic events assessment with RNAi and available inhibitors, can be
used to assess tumor dependency (cells with the aberration will be sensitive to gene
inhibition, whereas those without will not). Aberrations that are not directly targetable with
available inhibitors can be assessed through synthetic lethal screens using siRNA druggable
libraries and drug screens. Candidate dependencies can be subsequently validated in pre-
clinical models before evaluation in clinical trials. By identifying the genetic alteration and
then identifying ways of targeting it, allows the genomic biomarker to be established a
priori, cutting down the time to identify biomarkers of sensitivity during the drug
development process. As is sometimes the case, promising preclinical data do not readily
transfer to positive outcomes from early clinical trials. While inter- and intra-tumor genetic
heterogeneity almost certainly play a role in resistance to targeted therapies, other molecular
mechanisms can be teased out using the same approach described above. We can change the
cohort of samples interrogated with molecular profiling to identify biomarkers for resistance
or sensitivity to the targeted agent in question (i.e. before or after treatment, responders or
non-responders). Identification of targets that are selective to inhibitors already in clinical
trials will enhance the time to routine clinical use.
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